Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPKAPK5 | Q8IW41 | 10/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | CD63 | P08962 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822712 | 0.89 | MAPT (0.58) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL25822743 | 0.88 | SYK (0.48) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL25822735 | 0.85 | MAPKAPK5 (0.52) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL25822728 | 0.84 | SYK (0.55) | SYKCD63 | |
| SCHEMBL25822696 | 0.84 | MAPKAPK5 (0.56) | MAPKAPK5FYNSYKAURKACD63 | |
| SCHEMBL25822721 | 0.82 | MAPT (0.55) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL25822750 | 0.81 | SYK (0.42) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL25822740 | 0.81 | MAPKAPK5 (0.51) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL25822757 | 0.78 | SYK (0.47) | MAPTMAPK1AHRHTTMAPKAPK5 | |
| SCHEMBL26184431 | 0.75 | MAPT (0.54) | MAPTMAPK1MAPKAPK5FYNSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | MAPT 4275/4885MAPK1 355/4885AHR 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.